Fennec Pharmaceuticals (STU:RV41) ROCE % : -34.69% (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fennec Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was -34.69%.

Fennec Pharmaceuticals ROCE % Historical Data

The historical data trend for Fennec Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals ROCE % Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-79.59

-86.04

-72.11

-108.81

-59.82

Fennec Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-26.47	-40.66	141.17	-31.59	-34.69

Fennec Pharmaceuticals ROCE % Calculation

Fennec Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-11.601	/	( ( (25.43 - 4.351)	+	(24.634 - 6.926) )	/ 2 )
	=	-11.601	/	( (21.079	+	17.708)	/ 2 )
	=	-11.601	/	19.3935
	=	-59.82 %

Fennec Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-16.976	/	( ( (58.677 - 7.199)	+	(53.088 - 6.699) )	/ 2 )
	=	-16.976	/	( ( 51.478	+	46.389 )	/ 2 )
	=	-16.976	/	48.9335
	=	-34.69 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Fennec Pharmaceuticals (STU:RV41) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fennec Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

FENC:USA FRX:Canada

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals Headlines

No Headlines